Work Here?
Overview
Braveheart Bio develops therapeutics for hypertrophic cardiomyopathy by in-licensing and advancing late-stage drug candidates. Its lead drug, BHB-1893, is a selective small-molecule cardiac myosin inhibitor licensed from Hengrui Pharma for ex-China rights in a deal worth up to $1.1 billion, aimed at improving heart function by tempering myosin activity in HCM. The program includes Phase 2 trials in obstructive and non-obstructive HCM and a Phase 3 trial in China, with global late-stage development planned to begin in 2026. The company differentiates itself by pursuing a best-in-class profile with better efficacy, safety, and dosing, supported by a strong leadership team and high-profile investors, with the goal of delivering an approved therapy that provides meaningful clinical benefit and broader global access.
About Braveheart Bio
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$185M
Headquarters
San Francisco, California
Founded
2025
People at Braveheart Bio
People at Braveheart Bio who can refer or advise you
Simplify's Take
What believers are saying
- Phase 2 nHCM data showed sustained NT-proBNP reduction, supporting biomarker efficacy May 2026.
- 89% of oHCM patients responded to simplified dosing at ACC 2026 conference.
- NewCo model backs China-originated BHB-1893 with $65M upfront license September 2025.
What critics are saying
- BMS delays Camzyos label expansion, eroding differentiation narrative and market urgency in 9–14 months.
- Hengrui revokes ex-China license due to sanctions, halting global development in 6–10 months.
- FDA flags bias in Phase 3 design via Evanchik, triggering audit and 12-month delay in 5–8 months.
What makes Braveheart Bio unique
- BHB-1893 enables simplified 40–60 mg dosing without titration, unlike Camzyos.
- BHB-1893 delivers rapid LVOT-G reduction within days of treatment initiation.
- BHB-1893 shows minimal LVEF impact, preserving cardiac output better than rivals.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$185M
Above
Industry Average
Funded Over
1 Rounds
Industry standards
Benefits
Remote Work Options
Flexible Work Hours
Company Equity
Growth & Insights
6 month growth
↑ 7%1 year growth
↑ 16%2 year growth
↑ 16%Braveheart Bio is Hiring for 6 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Braveheart Bio
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$185M
Headquarters
San Francisco, California
Founded
2025
Braveheart Bio is Hiring for 6 Jobs on Simplify!
Find jobs on Simplify and start your career today